Morgan Stanley Altimmune, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Altimmune, Inc. stock. As of the latest transaction made, Morgan Stanley holds 835,407 shares of ALT stock, worth $3.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

835,407

Previous 657,247 27.11%

Holding current value

$3.02 Million

Previous $3.29 Million 1.61%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$3.5 - $7.71 $623,560 - $1.37 Million	178,160 Added 27.11%	835,407 $3.23 Million
Q1 2025 May 15, 2025	SELL	$5.0 - $7.45 $1.32 Million - $1.97 Million	-264,575 Reduced 28.7%	657,247 $3.29 Million
Q4 2024 Feb 14, 2025	SELL	$6.02 - $9.85 $2.25 Million - $3.68 Million	-373,763 Reduced 28.85%	921,822 $6.65 Million
Q3 2024 May 14, 2025	BUY	$5.5 - $8.1 $25,107 - $36,976	4,565 Added 0.35%	1,295,585 $7.95 Million
Q3 2024 Nov 14, 2024	BUY	$5.5 - $8.1 $25,107 - $36,976	4,565 Added 0.35%	1,295,585 $7.95 Million
Q2 2024 May 14, 2025	BUY	$5.91 - $10.23 $2.18 Million - $3.78 Million	369,198 Added 40.05%	1,291,020 $8.59 Million
Q2 2024 Oct 17, 2024	SELL	$5.91 - $10.23 $5.44 Million - $9.42 Million	-920,928 Reduced 41.63%	1,291,020 $8.59 Million
Q2 2024 Aug 14, 2024	SELL	$5.91 - $10.23 $5.44 Million - $9.42 Million	-920,928 Reduced 41.63%	1,291,020 $8.59 Million
Q1 2024 Oct 17, 2024	BUY	$8.22 - $13.81 $7.57 Million - $12.7 Million	920,928 Added 71.33%	2,211,948 $22.5 Million
Q1 2024 Aug 16, 2024	BUY	$8.22 - $13.81 $9.63 Million - $16.2 Million	1,171,047 Added 112.5%	2,211,948 $22.5 Million
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $9.63 Million - $16.2 Million	1,171,047 Added 112.5%	2,211,948 $22.5 Million
Q4 2023 Aug 16, 2024	SELL	$2.14 - $11.62 $535,254 - $2.91 Million	-250,119 Reduced 19.37%	1,040,901 $11.7 Million
Q4 2023 Feb 13, 2024	BUY	$2.14 - $11.62 $1.19 Million - $6.47 Million	556,843 Added 115.04%	1,040,901 $11.7 Million
Q3 2023 Nov 15, 2023	SELL	$2.4 - $3.45 $1.43 Million - $2.06 Million	-596,540 Reduced 55.2%	484,058 $1.26 Million
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $1.02 Million - $1.76 Million	295,077 Added 37.56%	1,080,598 $3.81 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $1.47 Million - $5.91 Million	350,937 Added 80.75%	785,521 $3.31 Million
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $1.38 Million - $2.59 Million	-157,326 Reduced 26.58%	434,584 $7.15 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $8.35 Million - $17.5 Million	-782,114 Reduced 56.92%	591,910 $7.56 Million
Q2 2022 Oct 27, 2022	SELL	$3.94 - $11.77 $133,625 - $399,179	-33,915 Reduced 2.41%	1,374,024 $16.1 Million
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $133,625 - $399,179	-33,915 Reduced 2.41%	1,374,024 $16.1 Million
Q1 2022 Oct 27, 2022	BUY	$5.9 - $9.45 $200,098 - $320,496	33,915 Added 2.47%	1,407,939 $8.57 Million
Q1 2022 May 13, 2022	BUY	$5.9 - $9.45 $1.51 Million - $2.42 Million	255,596 Added 22.18%	1,407,939 $8.57 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $3.74 Million - $5.37 Million	430,539 Added 59.65%	1,152,343 $10.6 Million
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $6.08 Million - $12.1 Million	721,804 New	721,804 $8.16 Million

Others Institutions Holding ALT

# of Institutions

223

Shares Held

36.5M

Call Options Held

4.92M

Put Options Held

4.18M

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $177M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account